Retinal Therapeutics Research Group, Save Sight Institute, Department of Clinical Ophthalmology, The University of Sydney, Level 2, South Block, Sydney Eye Hospital, Macquarie St, Sydney, NSW 2000, Australia.
Int J Biochem Cell Biol. 2009 Dec;41(12):2368-71. doi: 10.1016/j.biocel.2009.07.011. Epub 2009 Jul 29.
Vascular endothelial growth factor-A (VEGF-A), first described as "vascular permeability factor", is a critical molecule in the pathogenesis of diabetic retinopathy at several levels. Previous studies have outlined the importance of VEGF-A in mediating vascular pathology in both experimental models and clinical diabetic retinopathy, which are characterized by retinal vascular leakage, preretinal neovascularisation and neuronal degeneration. Paradoxically, recent reports have emphasized the potential neurotrophic effects of VEGF-A on the quiescent vasculature, as well as its direct and indirect protective effects on retinal neurons. VEGF-A has also been identified as an important signalling regulator in the normal central nervous system. Consequently, anti-VEGF therapy for diabetic retinopathy has become a controversal issue. This review outlines recently developed concepts relating to the role of VEGF-A in the pathogenesis of diabetic retinopathy, with particular emphasis on its implications for clinical practice.
血管内皮生长因子-A(VEGF-A)最初被描述为“血管通透性因子”,在多个层面上都是糖尿病性视网膜病变发病机制中的关键分子。先前的研究已经概述了 VEGF-A 在介导实验模型和临床糖尿病性视网膜病变中的血管病变中的重要性,其特征是视网膜血管渗漏、视网膜前新生血管形成和神经元变性。矛盾的是,最近的报告强调了 VEGF-A 对静止血管的潜在神经营养作用,以及其对视网膜神经元的直接和间接保护作用。VEGF-A 也已被确定为正常中枢神经系统中的重要信号调节因子。因此,抗 VEGF 治疗糖尿病性视网膜病变已成为一个有争议的问题。本综述概述了与 VEGF-A 在糖尿病性视网膜病变发病机制中的作用相关的最新概念,特别强调了其对临床实践的意义。